Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.557 CHF
403.32 M CHF
922.12 M CHF
115.69 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Founded
1998
ISIN
US40637H1095
FIGI
BBG00LVDJMV7
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027Yield to maturity
—
Maturity date
Mar 1, 2027
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028Yield to maturity
—
Maturity date
Aug 15, 2028
See all RV7 bonds
Curated watchlists where RV7 is featured.
Frequently Asked Questions
The current price of RV7 is 44.991 CHF — it has increased by 5.83% in the past 24 hours. Watch Halozyme Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Halozyme Therapeutics, Inc. stocks are traded under the ticker RV7.
We've gathered analysts' opinions on Halozyme Therapeutics, Inc. future price: according to them, RV7 price has a max estimate of 72.06 CHF and a min estimate of 40.38 CHF. Watch RV7 chart and read a more detailed Halozyme Therapeutics, Inc. stock forecast: see what analysts think of Halozyme Therapeutics, Inc. and suggest that you do with its stocks.
RV7 stock is 5.52% volatile and has beta coefficient of 0.12. Track Halozyme Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Halozyme Therapeutics, Inc. there?
Today Halozyme Therapeutics, Inc. has the market capitalization of 6.83 B, it has decreased by −0.73% over the last week.
Yes, you can track Halozyme Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Halozyme Therapeutics, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
RV7 earnings for the last quarter are 1.22 CHF per share, whereas the estimation was 0.99 CHF resulting in a 23.77% surprise. The estimated earnings for the next quarter are 1.28 CHF per share. See more details about Halozyme Therapeutics, Inc. earnings.
Halozyme Therapeutics, Inc. revenue for the last quarter amounts to 258.43 M CHF, despite the estimated figure of 226.84 M CHF. In the next quarter, revenue is expected to reach 270.15 M CHF.
RV7 net income for the last quarter is 131.04 M CHF, while the quarter before that showed 104.54 M CHF of net income which accounts for 25.34% change. Track more Halozyme Therapeutics, Inc. financial stats to get the full picture.
No, RV7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 1, 2025, the company has 350 employees. See our rating of the largest employees — is Halozyme Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Halozyme Therapeutics, Inc. EBITDA is 606.44 M CHF, and current EBITDA margin is 62.32%. See more stats in Halozyme Therapeutics, Inc. financial statements.
Like other stocks, RV7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Halozyme Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.